Featured Posters & Presentations
Lyfgenia
Efficacy, safety, and health-related quality of life (HRQOL) in patients with sickle cell disease (SCD) who have received lovotibeglogene autotemcel (lovo-cel) gene therapy: Up to 60 months of follow-up.
Authors: Kanter JA.
Zynteglo
Sustained efficacy, safety, and improved quality of life in adult and pediatric patients with transfusion-dependent β-thalassemia up to 9 years post treatment with betibeglogene autotemcel (beti-cel).
Authors: Thompson AA.
Zynteglo
Improvement in iron burden in patients with transfusion-dependent β-thalassemia (TDT) treated with betibeglogene autotemcel (beti-cel) gene therapy: up to 9 years of follow-up.
Authors: Kwiatkowski JL.